SCHEMBL458942

SCHEMBL458942

CCNC(=O)c1ccccc1C

nearest known ligand 0.66

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HPGD P15428 7/20 0.66
SMN1; SMN2 Q16637 6/20 0.58
MAPK1 P28482 1/20 0.58
NPC1 O15118 1/20 0.57
RAB9A P51151 1/20 0.57
KMT2A Q03164 2/20 0.55
MEN1 O00255 1/20 0.55
P2RX7 Q99572 1/20 0.54
L3MBTL1 Q9Y468 2/20 0.53
ALDH1A1 P00352 1/20 0.53
TP53 P04637 1/20 0.53
LMNA P02545 1/20 0.53
HTT P42858 2/20 0.52
TSHR P16473 1/20 0.52
GAA P10253 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31483721 0.87 HTT (0.64) HPGDKMT2AL3MBTL1ALDH1A1HTT
SCHEMBL26417076 0.87 HTT (0.64) HPGDKMT2AL3MBTL1ALDH1A1HTT
SCHEMBL4155532 0.85 KMT2A (0.50) HPGDMAPK1NPC1RAB9AKMT2A
SCHEMBL13477779 0.85 ALDH1A1 (0.58) HPGDSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL31686014 0.85 HPGD (0.64) HPGDSMN1; SMN2MAPK1NPC1RAB9A
SCHEMBL461599 0.85 HPGD (0.64) HPGDSMN1; SMN2MAPK1NPC1RAB9A
SCHEMBL10604035 0.84 HPGD (0.66) HPGDSMN1; SMN2MAPK1NPC1RAB9A
SCHEMBL23689774 0.82 HPGD (0.64) HPGDSMN1; SMN2MAPK1NPC1RAB9A
SCHEMBL11146831 0.82 HPGD (0.64) HPGDSMN1; SMN2MAPK1NPC1RAB9A
SCHEMBL17214430 0.82 HPGD (0.64) HPGDSMN1; SMN2MAPK1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3303291-A1 ROR GAMMA (ROR ) MODULATORS Lead Pharma Holding B.V. (NL) 2018-04-11 EP claimed
WO-2016193452-A1 ROR GAMMA (RORγ) MODULATORS LEAD PHARMA CEL MODELS IP B.V. (NL) 2016-12-08 WO claimed
CN-103649087-A Substituted imidazopyridines and intermediates thereof BAYER IP GMBH 2014-03-19 CN claimed
EP-0287421-B1 PROCESS FOR THE CYCLIC PRODUCTION OF HYDROGEN PEROXIDE ELF ATOCHEM S.A. (FR) 1991-06-05 EP claimed
US-4803063-A REDOX REACTION OF QUINONES IN AROMATIC AMIDE SOLVENT ATOCHEM (FR) 1989-02-07 US claimed
EP-0287421-A1 Process for the cyclic production of hydrogen peroxide ELF ATOCHEM S.A. (FR) 1988-10-19 EP claimed
US-12628827-B2 Isoxazoline compounds and their use as pest control agents PI INDUSTRIES LIMITED (IN) 2026-05-19 US disclosed
CN-117355373-B Ethylene oligomerization process 切弗朗菲利浦化学公司 2025-05-16 CN disclosed
EP-4545620-A2 ETHYLENE OLIGOMERIZATION PROCESSES Chevron Phillips Chemical Company LP (US) 2025-04-30 EP disclosed
CN-113227089-B Substituted 6-azabenzimidazole compounds as HPK1 inhibitors 吉利德科学公司 2024-07-05 CN disclosed
CN-118044519-A Molecules having pesticidal utility, and intermediates, compositions and methods related thereto 科迪华农业科技有限责任公司 2024-05-17 CN disclosed
US-20240057604-A1 ISOXAZOLINE COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS PI INDUSTRIES LTD. (IN) 2024-02-22 US disclosed
CN-110072842-B Molecules having pesticidal utility, and intermediates, compositions and methods related thereto 科迪华农业科技有限责任公司 2024-02-02 CN disclosed
US-20070060510-A1 Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2007-03-15 US disclosed
US-7176208-B2 Prevent reproduction of hepatitis virus ENANTA PHARMACEUTICALS, INC. (US) 2007-02-13 US disclosed
EP-0287421-B1 PROCESS FOR THE CYCLIC PRODUCTION OF HYDROGEN PEROXIDE ELF ATOCHEM S.A. (FR) 1991-06-05 EP disclosed
US-4803063-A REDOX REACTION OF QUINONES IN AROMATIC AMIDE SOLVENT ATOCHEM (FR) 1989-02-07 US disclosed
EP-0287421-A1 Process for the cyclic production of hydrogen peroxide ELF ATOCHEM S.A. (FR) 1988-10-19 EP disclosed
US-4083997-A ANTIDEPRESSANTS SANDOZ, INC. (US) 1978-04-11 US disclosed
US-3994961-A ANTIDEPRESSANTS SANDOZ, INC. (US) 1976-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12628827-B2 Isoxazoline compounds and their use as pest control agents HCN1, CBR3, SCN1B HPGD 4270/4885SMN1; SMN2 1742/4885MAPK1 3573/4885
US-20240057604-A1 ISOXAZOLINE COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS PRDX1, RDX, PRDX2 HPGD 2659/4885SMN1; SMN2 2742/4885MAPK1 2668/4885
US-20070060510-A1 Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors PRSS1, SPINT2, HPN HPGD 449/4885SMN1; SMN2 3819/4885MAPK1 1848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.